Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Free Cash Flow (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Free Cash Flow for 6 consecutive years, with -$4.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow rose 5.75% to -$4.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$15.4 million, a 19.92% decrease, with the full-year FY2024 number at -$13.3 million, down 10.95% from a year prior.
  • Free Cash Flow was -$4.1 million for Q3 2025 at Vivos Therapeutics, up from -$4.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$2.2 million in Q4 2021 to a low of -$6.2 million in Q1 2022.
  • A 5-year average of -$3.9 million and a median of -$3.9 million in 2025 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: plummeted 841.39% in 2021, then skyrocketed 60.48% in 2023.
  • Vivos Therapeutics' Free Cash Flow stood at -$2.2 million in 2021, then plummeted by 44.86% to -$3.2 million in 2022, then rose by 15.97% to -$2.7 million in 2023, then fell by 15.0% to -$3.1 million in 2024, then tumbled by 32.91% to -$4.1 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Free Cash Flow are -$4.1 million (Q3 2025), -$4.3 million (Q2 2025), and -$3.9 million (Q1 2025).